Advances in the Drug Development and Quality Evaluation Principles of Oncolytic Herpes Simplex Virus

作者：Basma Eid Abdullah Ghorab, Tongtan Liu, Min Ying, Ping Wang, Meirong Qin, Jiayong Xing, Huadong Wang, Fuqiang Xu · 发表于：Viruses · 年份：2025 · DOI：10.3390/v17040581 · 被引用次数：3 · 研究领域：Virus-based gene therapy research、Herpesvirus Infections and Treatments、CAR-T cell therapy research

Oncolytic herpes simplex virus (oHSV) represents a promising therapeutic approach to treating cancers by virtue of its selective replication in and lysis of tumor cells, with stimulation of host antitumor immunity. At present, four OV drugs have been approved for the treatment of cancers worldwide, two of which are oHSV drugs that have received extensive attention, known as T-VEC and Delytact. This review discusses the history, mechanism of action, clinical development, quality control, and evaluation principles of oHSV products, including viral species and genetic modifications that have improved these products' therapeutic potential, limitations, and future directions. Integration of oHSVs with immunotherapeutic agents and conventional therapies has a promising future in the field of treatment of malignant tumors. Although much progress has been achieved, there is still much work to be done regarding the optimization of treatment protocols and the quality control of oncolytic virus drugs. The approval of various oncolytic virus therapies underlines their clinical relevance, safety, and efficacy, thereby paving the way for further research aimed at overcoming the existing limitations and enhancing patient responses.